NPM1 and acute myeloid leukemia: The second study, the trial KOMET-001, involved the phase I evaluation of KO-539 (ziftomenib) in adult relapsing/refractory AML patients: in a heavily pre-treated cohort of relapsed/refractory NPM1-mut AML patients, an overall response rate of 40% and a complete response rate of 35% were observed [120].